PSMAI cut-off value for mortality in men: 680.1 mm2/m2

The unenhanced CT image of a 73-year-old male patient (A) at the L3

ASCO 2023: LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies

Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu- PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

PDF) Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [68Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy

Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients

SARCLISA® (isatuximab-irfc) ICARIA-MM Phase 3 Trial Results

ESMO 2022: Lu-PSMA for Prostate Cancer Treatment

PSMAI cut-off value for mortality in men: 680.1 mm2/m2